Background
Methods
Study design and subjects
Demographic and clinical characteristics of the study groups | Proteomics | Western Blots | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Healthy controls (n = 20) | Patients with AIS (n = 40) | P value | Healthy controls (n = 33) | Patients with AIS (n = 66) | P value | Patients with AIS due to non-LVO (n = 33) | Patients with AIS due to LVO (n = 33) | P value | AIS with good collaterals (n = 17) | AIS with poor collaterals (n = 16) | P value | |
Characteristics | ||||||||||||
Age, median (IQR), years | 52 (47.5–59) | 56 (47–63) | 0.602 | 55 (45–62) | 55 (48–63) | 0.711 | 59 (51–65) | 54 (46–59) | 0.188 | 56 (53–59) | 50.5 (43.5–59.75) | 0.250 |
Female, n (%) | 10 (50.0) | 15 (37.5) | 0.280 | 15 (45.5) | 21 (31.8) | 0.187 | 11 (33.3) | 10 (30.3) | 0.795 | 4 (23.5) | 6 (37.5) | 0.399 |
Systolic blood pressure, mmHg | 129.0 (17.4) | 141.5 (17.6) | 0.015 | 129.9 (16.3) | 145.9 (22.2) | 0.000 | 149.1 (23.8) | 142.7 (20.0) | 0.247 | 146.2 (21.2) | 139.0 (18.0) | 0.319 |
Diastolic blood pressure, mmHg | 77.5 (10.8) | 82.2 (10.1) | 0.115 | 79.6 (10.2) | 85.5 (10.8) | 0.012 | 86.8 (11.3) | 84.2 (10.1) | 0.339 | 86.6 (8.6) | 81.7 (10.8) | 0.172 |
Medical history, n (%) | ||||||||||||
Hypertension | 8 (40.0) | 27 (67.5) | 0.065 | 11 (33.3) | 41 (62.1) | 0.007 | 19 (57.6) | 22 (66.7) | 0.454 | 12 (70.6) | 10 (62.5) | 0.635 |
Diabetes mellitus | 2 (10.0) | 10 (25.0) | 0.203 | 2 (6.1) | 16 (24.2) | 0.027 | 6 (18.2) | 10 (30.3) | 0.257 | 6 (35.3) | 3 (18.8) | 0.301 |
Coronary heart disease | 3 (15.0) | 4 (10.0) | 0.529 | 5 (15.2) | 5 (7.6) | 0.243 | 2 (6.1) | 3 (9.1) | 0.458 | 3 (17.6) | 0 (0.0) | 0.082 |
Hypercholesterolemia | 3 (15.0) | 5 (12.5) | 0.735 | 3 (9.1) | 6 (9.1) | 1.000 | 3 (9.1) | 3 (9.1) | 1.000 | 2 (11.8) | 1 (6.3) | 0.596 |
Current or previous smoking | 7 (35.0) | 18 (45.0) | 0.561 | 9 (27.3) | 32 (48.5) | 0.044 | 16 (48.5) | 16 (48.5) | 1.000 | 10 (58.8) | 6 (37.5) | 0.233 |
Heavy alcohol use | 2 (10.0) | 10 (25.0) | 0.203 | 6 (18.2) | 22 (33.3) | 0.117 | 11 (33.3) | 11 (33.3) | 1.000 | 7 (41.2) | 4 (25.0) | 0.340 |
Blood test, mean (SD) | ||||||||||||
HCY | 11.0 (4.3) | 16.1 (8.9) | 0.023 | 11.3 (3.7) | 14.7 (6.6) | 0.008 | 13.8 (5.2) | 15.6 (7.6) | 0.264 | 14.3 (7.2) | 17.0 (7.8) | 0.326 |
Cholesterol | 3.9 (0.7) | 3.6 (0.9) | 0.364 | 3.9 (0.8) | 3.9 (1.0) | 0.980 | 4.1 (1.0) | 3.6 (1.0) | 0.075 | 3.7 (1.0) | 3.6 (0.9) | 0.795 |
Triglyceride | 1.6 (0.9) | 1.4 (0.7) | 0.360 | 1.5 (0.8) | 1.5 (1.0) | 0.977 | 1.3 (0.6) | 1.7 (1.3) | 0.128 | 1.5 (0.8) | 2.0 (1.6) | 0.284 |
LDL | 2.3 (0.6) | 2.1 (0.8) | 0.541 | 2.3 (0.7) | 2.3 (0.9) | 0.899 | 2.6 (0.9) | 2.1 (0.7) | 0.013 | 2.1 (0.7) | 2.0 (0.7) | 0.674 |
CRP | 7.1 (17.3) | 2.1 (0.8) | 0.345 | 5.3 (13.8) | 5.1 (8.2) | 0.939 | 5.2 (7.0) | 5.0 (9.3) | 0.895 | 2.3 (4.2) | 7.8 (12.1) | 0.094 |
Sample collection and preparation
iTRAQ-based quantitative proteomics analysis and Western blots validation
Statistical analyses
Results
Clinical characteristics of patients
Quantitative proteomic analysis reveals a specific proteomic profile in AIS due to LVO
Validation of potential biomarkers by Western blots analysis
Proteins | Healthy controls (n = 33) | Patients with AIS due to non-LVO (n = 33) | Patients with AIS due to LVO (n = 33) | P value | Pa value | Pb value | Pc value |
---|---|---|---|---|---|---|---|
IGF2 | 0.86 ± 0.24 | 0.90 ± 0.50 | 1.19 ± 0.42 | 0.001 | 0.948 | 0.001 | 0.017 |
LYVE1 | 0.97 ± 0.50 | 0.99 ± 0.49 | 1.61 ± 0.56 | < 0.001 | 0.998 | < 0.001 | < 0.001 |
PPBP | 0.98 ± 0.37 | 1.23 ± 0.55 | 1.58 ± 0.78 | < 0.001 | 0.081 | 0.001 | 0.045 |
THBS1 | 0.43 ± 0.26 | 0.62 ± 0.29 | 1.13 ± 0.88 | < 0.001 | 0.030 | < 0.001 | 0.010 |
Proteins | ORa (95% CIa) | Pa value | ORb (95% CIb) | Pb value | AUC (95% CI) | Pc value |
---|---|---|---|---|---|---|
IGF2 | 17.365 (2.862–105.358) | 0.002 | 47.564 (5.133–440.757) | 0.001 | 0.731 (0.609–0.853) | 0.001 |
LYVE1 | 10.320 (2.986–35.669) | < 0.001 | 7.707 (2.215–26.813) | 0.001 | 0.813 (0.707–0.919) | < 0.001 |
PPBP | 7.682 (2.201–26.813) | 0.001 | 8.163 (1.903–35.014) | 0.005 | 0.754 (0.638–0.870) | < 0.001 |
THBS1 | 13.282 (2.630–67.079) | 0.002 | 14.132 (2.401–83.185) | 0.003 | 0.769 (0.652–0.885) | < 0.001 |
Proteins | AIS with good collaterals (n = 17) | AIS with poor collaterals (n = 16) | P value | ORa (95% CIa) | Pa value | ORb (95% CIb) | Pb value |
---|---|---|---|---|---|---|---|
IGF2 | 1.35 ± 0.41 | 1.02 ± 0.35 | 0.022 | 0.115 (0.016–0.841) | 0.033 | 0.115 (0.015–0.866) | 0.036 |
LYVE1 | 1.82 ± 0.58 | 1.39 ± 0.42 | 0.026 | 0.183 (0.036–0.918) | 0.039 | 0.028 (0.002–0.334) | 0.005 |
PPBP | 1.37 ± 0.73 | 1.81 ± 0.77 | 0.111 | 1.939 (0.707–5.321) | 0.198 | 2.806 (0.933–8.439) | 0.066 |
THBS1 | 0.72 ± 0.42 | 1.56 ± 1.02 | 0.005 | 4.257 (1.273–14.228) | 0.019 | 3.294 (1.158–9.372) | 0.025 |